Luke Halpern is a journalist who writes for Pharmacy Times, covering a wide range of topics related to pharmacy and healthcare. With a background in journalism and a passion for healthcare, Luke's articles provide valuable insights and information to healthcare professionals and patients alike. His work has also been featured in The Massachusetts Daily Collegian.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Luke's coverage focuses heavily on healthcare and pharmaceutical topics, with a strong emphasis on citing data. He appears to prefer articles featuring case studies, treatment breakthroughs, and the impact of medical interventions. Therefore, he would likely be interested in pitches that provide access to credible experts who can offer insights into recent clinical trials or research findings in these areas.
Given Luke's focus on specific medical conditions and treatments, providing him with sources who have direct experience working with patients or carrying out related research may increase the chances of successful outreach efforts.
It should be noted that Luke does not appear to have a specific geographic focus but rather seems to cover global developments in healthcare and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Luke Halpern
The tablets become the first and only nilotinib with no mealtime restrictions indicated for this population.
By: Luke Halpern
When compared to established diagnostic assays such as the basophil activation test, the Hoxb8 mast cell activation test demonstrates similar precision.
By: Luke Halpern
GNSC-001 is a first-in-class gene therapy designed to offer long-term relief of musculoskeletal diseases such as osteoarthritis.
By: Luke Halpern
Listen Asthma was associated with memory and executive function difficulties in children and could be more severe if asthma onset is earlier
By: Luke Halpern
Severity of a COVID-19 illness could be determined by examining autoantibodies in the nasal cavity, allowing more personalized treatment protocols.
By: Luke Halpern, Kennedy Ferruggia
Through an assignment to create a TikTok infomercial, students master new concepts and have positive educational experiences via social media.
By: Luke Halpern
No acute serious bacterial infections were observed in a trial of patients with the debilitating immune disorder, a strong mark of safety and tolerability.
By: Luke Halpern
As a rare and serious pediatric disorder, Stargardt disease can cause vision complications in patients.
By: Luke Halpern
Commonly cited factors influencing uptake of pneumococcal vaccination included knowledge of pneumococcal disease and vaccine benefits, recommendations from health authorities, and perceived risk of infection.
By: Luke Halpern
Intravenous immunoglobulin (IVIG) has proven efficacy in autoimmune neuropathies, with mixed but promising outcomes in severe COVID-19 cases and post-acute sequelae of SARS-CoV-2 infection trials.
(833) 317-6278 
